Citadel Advisors’s Kyntra Bio KYNB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,196
| Closed | -$9.27K | – | 13299 |
|
|
2025
Q1 | $9.27K | Sell |
1,196
-388
| -24% | -$4.65K | ﹤0.01% | 13607 |
|
|
2024
Q4 | $21K | Buy |
1,584
+204
| +15% | +$1.9K | ﹤0.01% | 13150 |
|
|
2024
Q3 | $13.8K | Sell |
1,380
-2,984
| -68% | -$45K | ﹤0.01% | 13045 |
|
|
2024
Q2 | $97.3K | Buy |
4,364
+1,304
| +43% | +$40.3K | ﹤0.01% | 10953 |
|
|
2024
Q1 | $180K | Buy |
3,060
+2,344
| +327% | +$101K | ﹤0.01% | 10490 |
|
|
2023
Q4 | $15.9K | Buy |
716
+464
| +184% | +$7K | ﹤0.01% | 12816 |
|
|
2023
Q3 | $5.44K | Sell |
252
-15,240
| -98% | -$598K | ﹤0.01% | 13392 |
|
|
2023
Q2 | $1.05M | Buy |
15,492
+13,684
| +757% | +$5.66M | ﹤0.01% | 6363 |
|
|
2023
Q1 | $843K | Sell |
1,808
-316
| -15% | -$167K | ﹤0.01% | 7166 |
|
|
2022
Q4 | $851K | Buy |
2,124
+1,196
| +129% | +$458K | ﹤0.01% | 7130 |
|
|
2022
Q3 | $302K | Sell |
928
-388
| -29% | -$125K | ﹤0.01% | 9572 |
|
|
2022
Q2 | $347K | Buy |
1,316
+172
| +15% | +$43.9K | ﹤0.01% | 9483 |
|
|
2022
Q1 | $344K | Buy |
1,144
+88
| +8% | +$30.7K | ﹤0.01% | 10279 |
|
|
2021
Q4 | $372K | Sell |
1,056
-480
| -31% | -$149K | ﹤0.01% | 10422 |
|
|
2021
Q3 | $392K | Sell |
1,536
-2,588
| -63% | -$917K | ﹤0.01% | 10453 |
|
|
2021
Q2 | $2.75M | Buy |
4,124
+772
| +23% | +$445K | ﹤0.01% | 5818 |
|
|
2021
Q1 | $2.91M | Sell |
3,352
-544
| -14% | -$579K | ﹤0.01% | 5521 |
|
|
2020
Q4 | $3.61M | Buy |
3,896
+2,188
| +128% | +$2.3M | ﹤0.01% | 4256 |
|
|
2020
Q3 | $1.76M | Buy |
1,708
+168
| +11% | +$181K | ﹤0.01% | 4967 |
|
|
2020
Q2 | $1.56M | Buy |
1,540
+368
| +31% | +$342K | ﹤0.01% | 5003 |
|
|
2020
Q1 | $1.02M | Sell |
1,172
-1,456
| -55% | -$1.45M | ﹤0.01% | 5306 |
|
|
2019
Q4 | $2.82M | Sell |
2,628
-352
| -12% | -$359K | ﹤0.01% | 3874 |
|
|
2019
Q3 | $2.75M | Buy |
2,980
+1,472
| +98% | +$1.62M | ﹤0.01% | 3989 |
|
|
2019
Q2 | $1.7M | Sell |
1,508
-1,680
| -53% | -$1.84M | ﹤0.01% | 4792 |
|
|
2019
Q1 | $4.33M | Buy |
3,188
+884
| +38% | +$1.2M | ﹤0.01% | 3213 |
|
|
2018
Q4 | $2.67M | Buy |
2,304
+700
| +44% | +$787K | ﹤0.01% | 3715 |
|
|
2018
Q3 | $2.44M | Buy |
1,604
+624
| +64% | +$961K | ﹤0.01% | 4069 |
|
|
2018
Q2 | $1.53M | Sell |
980
-52
| -5% | -$67.8K | ﹤0.01% | 4505 |
|
|
2018
Q1 | $1.19M | Sell |
1,032
-452
| -30% | -$595K | ﹤0.01% | 4531 |
|
|
2017
Q4 | $1.76M | Sell |
1,484
-168
| -10% | -$211K | ﹤0.01% | 3814 |
|
|
2017
Q3 | $2.22M | Buy |
1,652
+700
| +74% | +$738K | ﹤0.01% | 3281 |
|
|
2017
Q2 | $769K | Buy |
952
+8
| +0.8% | +$5.57K | ﹤0.01% | 4495 |
|
|
2017
Q1 | $582K | Buy |
+944
| New | +$575K | ﹤0.01% | 4785 |
|
|
2016
Q3 | – | Sell |
-716
| Closed | -$294K | – | 7370 |
|
|
2016
Q2 | $294K | Sell |
716
-272
| -28% | -$125K | ﹤0.01% | 5244 |
|
|
2016
Q1 | $526K | Buy |
988
+744
| +305% | +$371K | ﹤0.01% | 4347 |
|
|
2015
Q4 | $186K | Buy |
244
+204
| +510% | +$135K | ﹤0.01% | 5896 |
|
|
2015
Q3 | $22K | Buy |
+40
| New | +$24.2K | ﹤0.01% | 8093 |
|
Other funds holding KYNB
AC
VCM
VFT
Citadel Advisors's KYNB Position: Q1 2026 in Review
Citadel Advisors sold out of Kyntra Bio (KYNB) in Q1 2026, closing a stake of 16,756 shares — an estimated $147K sold.
Citadel Advisors first reported a position in KYNB in Q1 2015 and held it in 38 quarters. The position peaked at $33.6M in Q2 2019. 32 funds tracked by Wall St. Rank hold KYNB as of Q1 2026.
- Citadel Advisors reported no remaining Kyntra Bio position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 16,756 Kyntra Bio shares in Q1 2026, an estimated $147K.
- Citadel Advisors first reported a position in Kyntra Bio in Q1 2015 and held it in 38 quarters.
- Citadel Advisors's Kyntra Bio position peaked at $33.6M in Q2 2019.
- 32 funds tracked by Wall St. Rank held Kyntra Bio as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.